The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat neurofibromatosis type 1 (NF1), a rare genetic disorder affecting approximately 100,000 ...

In this week's InnovationRx newsletter, federal judges halt Trump's cuts to NIH research payments, rural hospitals' ongoing ...

Daniel Pichl, Chief People Officer at SpringWorks Therapeutics (NASDAQ:SWTX), has recently sold a significant portion of his holdings in the company. According to a Form 4 filing with the SEC, Pichl ...

Edris Badreddin, Chief Operating Officer of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), sold 30,000 shares of the company's ...

Snagging its second U.S. FDA approval since being spun out of Pfizer Inc. in 2017, Springworks Therapeutics Inc. is aiming to position Gomekli (mirdametinib), cleared for neurofibromatosis type ...

Approval makes Gomekli the first treatment to be approved for both adults and pediatric patients for neurofibromatosis type 1 ...

SpringWorks Therapeutics (SWTX) has announced that the U.S. Food and Drug Administration has approved Gomekli, a small molecule MEK inhibitor, ...

Adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that are not amenable ...